0001640334-26-001574.txt : 20260918 0001640334-26-001574.hdr.sgml : 20260918 20260918113513 ACCESSION NUMBER: 0001640334-26-001574 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506(b) provides a "safer harbor" for a private offering FILED AS OF DATE: 20260918 DATE AS OF CHANGE: 20260918 EFFECTIVENESS DATE: 20260918 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aqur Biosciences, Inc. CENTRAL INDEX KEY: 0002094075 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 863835015 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-598066 FILM NUMBER: 261389520 BUSINESS ADDRESS: STREET 1: 2829 TOWNSGATE ROAD, SUITE 100 CITY: WESTLAKE VILLAGE STATE: CA ZIP: 91361 BUSINESS PHONE: 818-698-1006 MAIL ADDRESS: STREET 1: 2829 TOWNSGATE ROAD, SUITE 100 CITY: WESTLAKE VILLAGE STATE: CA ZIP: 91361 D 1 primary_doc.xml X0708 D LIVE 0002094075 Aqur Biosciences, Inc. 2829 TOWNSGATE ROAD SUITE 100 WESTLAKE VILLAGE CA CALIFORNIA 91361 818-698-1006 NEVADA None None Corporation true Michael A Fole 2829 Townsgate Road Suite 100 Westlake Village CA CALIFORNIA 91361 Executive Officer Jeffrey B Wolin 2829 Townsgate Road Suite 100 Westlake Village CA CALIFORNIA 91361 Executive Officer Director James Hess Leach 2829 Townsgate Road Suite 100 Westlake Village CA CALIFORNIA 91361 Executive Officer Michel F Denarie 2829 Townsgate Road Suite 100 Westlake Village CA CALIFORNIA 91361 Executive Officer Tomi K Sawyer 2829 Townsgate Road Suite 100 Westlake Village CA CALIFORNIA 91361 Executive Officer Pharmaceuticals Decline to Disclose 06b false 2026-09-03 false true true true false 0 Roth Capital Partners, LLC 15407 None None 888 San Clemente Suite 400 Newport Beach CA CALIFORNIA 92660 CA CALIFORNIA CT CONNECTICUT NV NEVADA OR OREGON true 1500000 1500000 0 Sale of Series B Convertible Preferred Stock and accompanying warrants in a private placement to accredited investors false 7 0 0 Roth Capital Partners, LLC was paid a fixed fee of $125,000 for advisory services related to the offering, but will not receive any sales commissions, finders' fees or other fees contingent upon subscriptions. 0 false Aqur Biosciences, Inc. /s/ Jeffrey B. Wolin Jeffrey B. Wolin President 2026-09-18